Biozep - an attractive investment opportunity

Global Ophthalmic Drugs Market size was valued at $27 billion in 2017 and is expected to reach $38 billion in 2023, corresponding to a CAGR of 6% from 2017 to 2023. It is noted that the increasing prevalence of eye diseases is the key factor driving the ophthalmic drugs market. 

According to the 2017 statistics suggested by the World Health Organization (WHO), around 253 million people are living with vision impairment, out of which 36 million are blind and nearly 217 million have moderate to severe vision impairment. It is also reported that chronic eye diseases are the main cause of vision loss, globally.

Biozep has an existing product pipeline based on novel Therapeutic Lipids for treatment of chronic eye diseases with initial proof-of-principle data.  Our Therapeutic Lipids will be classified as a first-in-class drug, targeting the cause of the disease and not only the symptoms. This is an important reason why Biozep is well positioned to take a substantial share of the future ophthalmic drug market. The company´s patented, novel drug concept target a substantial unmet medical need.

First half of 2019 Biozep will pursue an equity round for the purpose of completing preclinical studies and phase 1 studies in humans.

To learn more about Biozep and the planned equity round please contact Anne Kristin Holmeide, Managing director.  A business presentation will be shared on request.
​
Contact: Anne Kristin Holmeide at contact@biozep.com or at LinkedIn